This study investigated γδ T cell infiltration and anti-tumor function in small cell lung cancer (SCLC) using single-cell approaches on patient biospecimens, two clinical trial cohorts, and preclinical models to evaluate γδ T cells as therapeutic targets.
High γδ T cell infiltration predicted improved response to anti-PD-L1 immunotherapy in two practice-changing SCLC clinical trials; γδ T cells maintained a cytotoxic transcriptional profile despite PD-1 expression, were effective in tarlatamab (DLL3-CD3 BiTE)-redirected SCLC killing, and zoledronate sensitized SCLC cells to γδ T cell-mediated killing.
Findings from preclinical models may not fully translate to patients; the predictive value of γδ T cell infiltration was assessed retrospectively in clinical trial cohorts; the MHC-I-independent mechanisms driving γδ T cell activity in SCLC require further mechanistic validation.
γδ T cell infiltration may serve as a biomarker for anti-PD-L1 response in SCLC, and zoledronate (FDA-approved) could be explored as a sensitizing agent to boost γδ T cell-mediated killing in SCLC patients.